Sionna Therapeutics, Inc. has reported its financial results for the fourth quarter and full year ended December 31, 2025. The company maintained a strong cash position with approximately $310.3 million in cash and cash equivalents, expected to fund operations into 2028.
In terms of pipeline updates, the ongoing precision CF phase 2a proof-of-concept trial with Sion-719 is on track, with topline data anticipated in mid-2026. Additionally, the ongoing phase 1 trial evaluating Sion-451 in proprietary dual combinations with Sion-2222 and Sion-109 in healthy volunteers is also on track, with topline data anticipated in mid-2026.
Regarding financial results, research and development expenses were $15.2 million for the fourth quarter of 2025 and $60.3 million for the year ended December 31, 2025. This is compared to $14.3 million and $57.3 million, respectively, for the same periods of 2024. General and administrative expenses were $8.4 million for the fourth quarter of 2025 and $28.7 million for the year ended December 31, 2025, compared to $3.9 million and $13.3 million, respectively, for the same periods of 2024. The net loss was $20.4 million for the fourth quarter of 2025 and $75.3 million for the year ended December 31, 2025, compared to a net loss of $15.8 million and $61.7 million, respectively, for the same periods of 2024.
The market has reacted to these announcements by moving the company's shares 0.67% to a price of $39.11. If you want to know more, read the company's complete 8-K report here.
